EMA OKs Scil to make reteplase for Actavis
This article was originally published in Scrip
The European Medicines Agency has approved Scil Proteins' Halle, Germany facilities for manufacturing reteplase on behalf of Actavis, which markets the recombinant protein for the treatment of myocardial infarction as Rapilysin.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.